Current systemic therapies for psoriasis: Where are we now?

Journal of the American Academy of Dermatology

Volumn 49, Issue 2 A, 2003, Pages 66-77

  Yamauchi, Paul S ^a   Rizk, Dalia ^a   Kormeili, Tanya ^a   Patnaik, Rickie ^a   Lowe, Nicholas J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIPSORIASIS AGENT; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CALCIPOTRIOL; CEFALOTIN; CHLORAMPHENICOL; COLCHICINE; COTRIMOXAZOLE; CYCLOSPORIN; ETRETIN; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PHENYTOIN; PROBENECID; PYRIMETHAMINE; RETINOID; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; TACROLIMUS; TETRACYCLINE; TIOGUANINE; UNINDEXED DRUG;

ACNE; ADJUVANT THERAPY; ALOPECIA; ANEMIA; ARTHRALGIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN PSEUDOTUMOR; CANCER; DERMATOMYOSITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; HEADACHE; HERPES; HUMAN; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERPIGMENTATION; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; KERATOSIS; KIDNEY FUNCTION; LEG ULCER; LEUKOPENIA; LIVER BIOPSY; LIVER FUNCTION; LIVER TOXICITY; LUNG FIBROSIS; LYMPHOMA; MALAISE; MOUTH ULCER; MYALGIA; NAUSEA; NEPHROTOXICITY; OLIGOSPERMIA; PARESTHESIA; PATIENT MONITORING; PHOTOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN DISEASE; SKIN TOXICITY; STOMATITIS; TERATOGENICITY; TREMOR; VOMITING;

EID: 0042133261     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/mjd.2003.550     Document Type: Review

References (83)

1. Gommans JM, van Hezik SJ, van Huystee BE. Flow cytometric quantification of T6-positive cells in psoriatic epidermis after PUVA and methotrexate therapy. Br J Dermatol 1987;116:661-6.
2. Newton JA, Camplejohn RS, Bowyer C, McGibbon DH, Wright NA. Study of psoriatic epidermal cell kinetics and cell death after oral methotrexate. Dermatologica 1985,171:469-73.
3. Gubner R, August A, Ginsberg V. Therapeutic suppression of tissue reactivity: effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1975;221:176-82.
4. Rees RB, Bennett JH, Bostick W. Aminopterin for psoriasis. Arch Dermatol 955;72:133-42.
5. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonist. Arch Dermatol 1958;78:200-3.
6. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478-85.
7. Weinstein GD, Frost P. Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971;103:33-8.
8. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993;28:466-9.
9. Lawrenz-Wolf B, Wehinger H. Reactivation of sunburn by methotrexate. Klin Padiatr 1988;200:335-8 [in German].
10. Paul C, Le Tourneau A, Cayuela JM, Devidas A, Robert C, Molinie V, et al. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol 199;133:867-71.
11. Shupack JL, Webster GF. Pancytopenia following low-dose oral methotrexate therapy for psoriasis. JAMA 1988;259:3594-6.
12. MacKinnon SK, Starkebaum G, Willkens RF. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1985;15:119-26.
13. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-6.
14. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. J Hepatol 1986;2:165-73.
15. Zachariae H, Heickendorff L, Sogaard H. The value of aminoterminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001;14:100-3.
16. Boffa MJ, Smith A, Chalmers RJ, Mitchell DM, Rowan B, Warnes TW, et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996;135:538-44.
17. Risteli J, Sogaard H, Oikarinen A, Risteli L, Karvonen J, Zachariae H. Aminoterminal propeptide of type III procollagen in methotrexate-induced liver fibrosis and cirrhosis. Br J Dermatol 1988;119:321-5.
18. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979;301:555.
19. Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256:3110-6.
20. Wentzell JM, Baughman RD, O'Connor GT, Bernier GM Jr. Cyclosporine in the treatment of psoriasis. Arch Dermatol 1987;123:163-5.
21. Picascia DD, Garden JM, Freinkel RK, Roenigk HH Jr. Treatment of resistant severe psoriasis with systemic cyclosporine. J Am Acad Dermatol 1987;17:408-14.
22. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998;39:464-75.
23. Shupack J, Abel E, Bauer E, Brown M, Drake L, Freinkel R, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997;36:423-32.
24. Berth-Jones J, Henderson CA, Munro CS, Rogers S, Chalmers RJ, Boffa MJ, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study. Br J Dermatol 1997;136:527-30.
25. Heule F, Meinardi MM, van Joost T, Bos JD. Low-dose cyclosporine effective in severe psoriasis: a double-blind study. Transplant Proc 1988;20:32-41.
26. Finzi AF, Mozzanica N, Cattaneo A, Chiappino G, Pigatto PD. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol 1989;21:91-7.
27. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991;324:277-84.
28. Kilic SS, Hacimustafaoglu M, Celebi S, Karadeniz A, Ildirim I. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol 2001;18:246-8.
29. Reitamo S, Erkko P, Remitz A, Lauerma A.I., Montonen O, Harjula K. Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study. Arch Dermatol 1993;129:1273-9.
30. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002;146:118-21.
31. Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999;141:279-82.
32. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999;41: S25-S28.
33. Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996;35:710-9.
34. Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 1997;136:531-5.
35. Srivastava T, Zwick DL, Rothberg PG, Warady BA. Posttransplant lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol 1999;13:748-54.
36. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
37. Valdimarsson H. Immunity during cyclosporine therapy. J Am Acad Dermatol 1990;23:1294-8.
38. Korstanje MJ, Hulsmans RF. Combination therapy cyclosporin A - PUVA in psoriasis. Acta Derm Venereol 1990;70:89-90.
39. Larsen FG, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen-Kudsk F. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993;100:623-7.
40. Lowe NJ, Lazarus V, Matt L. Systemic retinoid therapy for psoriasis. J Am Acad Dermatol 1988;19:186-91.
41. Ling MR. Acitretin: optimal dosing strategies. J Am Acad Dermatol 1999;41:S13-S17.
42. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999;41:S22-S24.
43. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24:591-4.
44. Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989;120:665-70.
45. Lebwohl M, Drake L, Menter A, Koo J, Gottlieb AB, Zanolli M, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001;45:544-53.
46. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol 2001;2:95-120.
47. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. Arch Dermatol 2000;136:1536-43.
48. Lowe NJ, David M. New retinoids for dermatologic diseases. Uses and toxicity. Dermatol Clin 1988;6:539-52.
49. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649-61.
50. Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975;65:537-42.
51. Marinari R, Fleischmajer R, Schragger AH, Rosenthal AL. Myco phenolic acid in the treatment of psoriasis: long-term administration. Arch Dermatol 1977;113:930-2.
52. Lynch WS, Roenigk HH Jr. Mycophenolic acid for psoriasis. Arch Dermatol 1977;113:1203-8.
53. Spatz S, Rudnicka A, McDonald CJ. Mycophenolic acid in psoriasis. Br J Dermatol 1978;98:429-35.
54. Gomez EC, Menendez L, Frost P. Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol 1979;1:531-7.
55. Geilen CC, Arnold M, Orfanos CE. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 2001;144:583-6.
56. Ameen M, Smith HR, Barker JN. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol 2001;26:480-3.
57. Grundmann-Kollmann M, Mooser G, Schraeder P, Zollner T, Kaskel P, Ochsendorf F, et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000;42:835-7.
58. Boyd AS, Neldner KH. Hydroxyurea therapy. J Am Acad Dermatol 1991;25:518-24.
59. Leavell UW Jr, Yarbro JW. Hydroxyurea. A new treatment for psoriasis. Arch Dermatol 1970;102:144-50.
60. Stein KM, Shelley WB, Weinberg RA. Hydroxyurea in the treatment of pustular psoriasis. Br J Dermatol 1971;85:81-5.
61. Rosten M. Hydroxyurea: a new antimetabolite in the treatment of psoriasis. Br J Dermatol 1971;85:177-81.
62. Moschella SL, Greenwald MA. Psoriasis with hydroxyurea. An 18-month study of 60 patients. Arch Dermatol 1973;107:363-8.
63. Layton AM, Sheehan-Dare RA, Goodfield MJ, Cotterill JA. Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol 1989;121:647-53.
64. Kumar B, Saraswat A, Kaur I. Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol 2001;40:530-4.
65. Kumar B, Saraswat A, Kaur I. Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol 2002;27:8-13.
66. Zackheim HS, Glogau RG, Fisher DA, Maibach HI. 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 1994;30:452-8.
67. Molin L, Thomsen K. Thioguanine treatment in psoriasis. Acta Derm Venereol 1987;67:85-8.
68. Silvis NG, Levine N. Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol 1999;135:433-7.
69. Mason C, Krueger GG. Thioguanine for refractory psoriasis: a 4-year experience. J Am Acad Dermatol 2001;44:67-72.
70. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995;22:894-8.
71. Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA. Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol 1993;32:923-5.
72. Gupta AK, Ellis CN, Siegel MT, Voorhees JJ. Sulfasalazine: a potential psoriasis therapy? J Am Acad Dermatol 1989;20:797-800.
73. Scerri L. Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol 1999;455:343-8.
74. Hacker SM, Ramos-Caro FA, Ford MJ, Flowers FP. Azathioprine: a forgotten alternative for treatment of severe psoriasis. Int J Dermatol 1992;31:873-4.
75. Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE. Tacrolimus (FK 506) - a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992;128:781-5.
76. The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996;132:419-23.
77. Pershadsingh HA. Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes. Expert Opin Investig Drugs 1999;8:1859-72.
78. Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000;136:609-16.
79. Menter MA, See JA, Amend WJ, Ellis CN, Krueger GG, Lebwohl M, et al. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol 1996;34(2 Pt 1):315-21.
80. Muchenberger S, Schoff E, Simon JC. The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis. Br J Dermatol 1997;137:587-9.
81. Ruzicka T, Sommerburg C, Braun-Falco O, Koster W, Lengen W, Lensing W, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 1990;126:482-6.
82. Lowe N, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24:591-4.
83. Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989;120:665-70.